BPA for palynziq

Ended Awarded Last action

Contract number
36E79722A0004
Awardee
Awarding agency
Task orders
1 $117,377 obligated

Award facts

Opportunity
  • VA797P12Q0002 Solicitation number
Combined order value
$117,377 Current and potential, with all options
Last date to order 100% complete
IDV ceiling 77% used
$151,685.00
Award type
Single award
Who can order
Only the awarding agency
Contracting staff
Set-aside
No set-aside
Competition
Full and Open Competition · 1 offer Multiple Award, Fair Opportunity
Pricing
Firm Fixed Price

Award details come from SAM.gov/FPDS.

About this IDV

This Blanket Purchase Agreement (BPA), awarded to BioMarin Pharmaceutical Inc. on October 15, 2021, establishes a framework for the supply of Palynziq (pegvaliase-pqpz) to the Veterans Affairs (VA) system through the GSA Schedule 61-IB for Pharmaceuticals and Drugs. The contract carries a ceiling value of $151,685 and extends through October 14, 2026, with performance conducted from BioMarin's location in Novato, California. The award was made as a single-award, non-set-aside procurement under the National Acquisition Center, which administers federal supply schedules for civilian government agencies. Palynziq is a specialty pharmaceutical indicated for reducing blood phenylalanine levels in adult patients with phenylketonuria, a rare metabolic disorder, making this contract essential for providing targeted therapeutic options to the veteran population.

Under this BPA framework, documented task orders include a February 4, 2022 BPA call to Veterans Integrated Service Network 23 valued at $117,376.50, representing a firm fixed price delivery order with a completion date of September 30, 2022. The contract structure leverages the existing GSA Pharmaceuticals and Drugs schedule to streamline procurement while maintaining favorable pricing through established government contract terms. BioMarin's authorization to issue orders under this BPA allows the VA to obtain this specialty pharmaceutical on an as-needed basis, supporting the agency's mission to provide comprehensive pharmaceutical care to the veteran population while benefiting from the economies of scale and pricing protections inherent in the GSA schedule vehicle.

Task orders

Task order Ordering agency Obligated Awarded
Pegvaliase-pqpz (PALYNZIQ) 36C26322N0466 Veterans Integrated Service Network 23 (VHA) $117,377

Transactions

Action Obligated Date
Supplemental Agreement for work within scope P00009 · 2026 public law pricing updates. $0
Exercise an Option P00008 · Exercise option year 4 on BPA 36E79722A0004. $0
Supplemental Agreement for work within scope P00007 · 2025 public law pricing updates $0
Exercise an Option P00006 · This modification is issued to exercise option year 3 on BPA 36E79722A0004. $0
Supplemental Agreement for work within scope P00005 · 2024 public law pricing updates $0
Exercise an Option P00004 · This modification is issued to exercise option year 2 on BPA 36E79722A0004. The period of performance is october 15, 2023 - october 14, 2024. $0
Supplemental Agreement for work within scope P00003 · 2023 public law pricing updates $0
Exercise an Option P00002 · Exercise BPA 36E79722A0004 option year 1 $0
Supplemental Agreement for work within scope P00001 · 2022 public law pricing updates $0
Original award $0

Quick answers

Who was awarded contract 36E79722A0004?

36E79722A0004 was awarded to Biomarin Pharmaceutical Inc. by National Acquisition Center (Headquarters) on October 15, 2021.

How much is contract 36E79722A0004 worth?

Orders under 36E79722A0004 have obligated $117,377. 36E79722A0004's own ceiling is $151,685.

How many orders have been placed under contract 36E79722A0004?

1 order has been placed under 36E79722A0004, the latest on February 4, 2022.

Who can order from contract 36E79722A0004?

36E79722A0004 is a single award blanket purchase agreement. Only the awarding agency can place orders on it.

Is contract 36E79722A0004 under another contract?

Yes. 36E79722A0004 is a blanket purchase agreement under 36F79721D0170, a federal supply schedule, on Pharmaceuticals and Drugs (FSS-61-IB).

Was contract 36E79722A0004 competed?

The extent of competition for 36E79722A0004 was full and open competition. The government received 1 offer.

On GovTribe

See this IDV's full record

  • Every order and transaction
  • The awardee's other awards and teaming partners
  • Similar IDVs and recompete opportunities
  • Ask GovTribe AI about this IDV